Stock Market News & Stocks to Watch from StraightStocks » treatment for melanoma

Taking Cancer Treatment to a New Level (OTC:PVCT)

Michael Vlaicu — Wed, 16 Sep 2009 04:11:03 +0000

Provectus Pharmaceuticals, Inc. (Public, OTC:PVCT) StocksHaven Investments profiles one of the most exciting up-and-coming anti-cancer companies in the industry, Provectus Pharmaceuticals (OTC:PVCT). They have one of the deepest pipelines of any small cap biotech, focusing on treatments for: Melanoma, Psoriasis, Atopic Dermatitis, Breast Cancer, and Liver Metastasis. With three drugs nearly ready to enter Phase III, including [...]

Genta to Stay Around 25 Cents – Analyst Blog

Zacks Market Commentaries — Fri, 05 Dec 2008 13:47:05 +0000

Genta Incorporated (GNTA) is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of cancer. The company's leading candidate, Genasense, got a non-approvable letter from the FDA in December 2006. As expected, in early December 2008, the FDA issued a complete response letter indicating that the company needs to conduct an additional clinical study for Genasense in order to receive approval for CLL.

Meanwhile, positive results from the AGENDA trial will support the worldwide filing of Genasense as a treatment for melanoma. However, results from the phase III trial are not expected before mid-2009.

Therefore, we rate the shares Hold with a revised target price of $0.25.

Maharathi Basu contributed to this report.

Read the full analyst report on GNTA

"GNTA" Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research

Genta to Stay Trading Below $1 – Analyst Blog

Zacks Market Commentaries — Fri, 26 Sep 2008 14:37:01 +0000

Genta Incorporated (GNTA) is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of cancer. The company's leading candidate, Genasense, got a 'non-approvable' notice from the FDA on December 15, 2006. The company filed an appeal with the FDA in April 2007 and got a positive response from the FDA in March 2008.

Additionally, positive results from the AGENDA trial will support the worldwide filing of Genasense as a treatment for melanoma. However, results from the phase III trial are not expected before mid-2009. Therefore, we rate the shares Hold with a target price of $0.70 on a market cap of $26 million.

In April 2008, the company reduced its workforce by approximately 30% in order to conserve cash. Genta also announced that it would seek a buyer for its sole marketed product, Ganite. We do not see the company attaining profitability in the near future. We believe that Genta shares are fairly valued at the current level.

Maharathi Basu contributed to this report.

Read the full analyst report on GNTA

"GNTA" Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research

Genta Goes Into Survival Mode

Zacks Market Commentaries — Wed, 20 Aug 2008 10:08:12 +0000

We maintain a Hold rating on Genta Incorporated (GNTA), a biopharmaceutical company focused on developing and commercializing drugs for the treatment of cancer.

Unfortunately, the company has entered into a survival mode due to the shortage of cash. With the non-approval of Genasense for chronic lymphocytic leukemia by FDA, the future of Genasense remains uncertain. In July 2007, the EMEA indicated that approval of Genasense in melanoma will require the conduct of another clinical study. Genta believes that the AGENDA trial will be able to address the EMEAs requirement adequately.

Positive data from this trial will enable the company for the worldwide filing of Genasense as a treatment for melanoma. However, we do not expect to see data from the trial before end-2008. The company had cash and marketable securities of only $16.3 million at June 30, 2008. It raised $3.1 million through the issuance of 6 million shares to institutional investors in February 2008 and issued $20 million senior notes with 15% interest rate in June 2008.

The sales of Genasense and Ganite outside the U.S. on a named patient/compassionate basis only provide the company with limited revenue which cannot offset high R&D costs due to the current phase III trial of AGNDA. In April 2008, the Company reduced its workforce by approximately 30% in order to conserve cash. Genta also announced that it would seek a buyer for its sole marketed product, Ganite.

We do not see the company attaining profitability in the near future. We believe that Genta shares are fairly valued at the current level. Our target price is $0.70 which corresponds to a market cap of $26 million.

Read the full analyst report on GNTA

"GNTA" Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research